A client with hemophilia has prolonged partial thromboplastin time (PTT) and normal prothrombin time (PT)
What does this laboratory result indicate about the client's condition?
The client has a normal coagulation profile.
The client may have a vitamin K deficiency.
The client likely has hemophilia.
The client is at risk for thrombosis.
The Correct Answer is C
Choice A rationale:
The client has a normal coagulation profile.
This choice is incorrect because the client's prolonged PTT suggests a problem with the intrinsic pathway of coagulation, which is typical in hemophilia.
A normal coagulation profile would show normal values for both PTT and PT.
Choice B rationale:
The client may have a vitamin K deficiency.
This choice is not applicable in this context.
A vitamin K deficiency primarily affects the extrinsic pathway of coagulation, leading to an elevated PT, but it does not typically affect the PTT, which is prolonged in hemophilia.
Choice C rationale:
The client likely has hemophilia.
This is the correct choice.
Hemophilia is characterized by a deficiency or dysfunction of clotting factors, most commonly factor VIII (hemophilia A) or factor IX (hemophilia B)
Prolonged PTT with normal PT is a classic laboratory finding in hemophilia.
Choice D rationale:
The client is at risk for thrombosis.
This choice is incorrect.
Hemophilia is associated with bleeding tendencies, not an increased risk of thrombosis.
Prolonged PTT indicates a reduced ability to form clots, making thrombosis less likely.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is A
Explanation
Choice A rationale:
Desmopressin acetate (DDAVP) is a medication used to stimulate the release of factor VIII and von Willebrand factor from endothelial cells.
It is particularly effective in patients with mild to moderate hemophilia A who have a functional von Willebrand factor.
DDAVP works by promoting the release of stored clotting factors from the endothelium, temporarily increasing their levels in the bloodstream.
This medication is administered intranasally, subcutaneously, intravenously, or orally, making it a versatile option for treatment in different clinical settings.
Choice B rationale:
Factor VIII concentrates are used for the replacement of factor VIII in patients with hemophilia A but do not stimulate the release of factor VIII and von Willebrand factor from endothelial cells.
Factor VIII concentrates are typically administered intravenously to replace the deficient clotting factor.
Choice C rationale:
Tranexamic acid is an antifibrinolytic agent used to prevent the breakdown of fibrin clots.
While it can help in managing bleeding episodes in patients with hemophilia, it does not stimulate the release of factor VIII or von Willebrand factor from endothelial cells.
Choice D rationale:
Gene therapy is an emerging treatment approach for hemophilia, but it does not stimulate the release of factor VIII and von Willebrand factor from endothelial cells.
Gene therapy aims to provide a long-term solution by introducing functional clotting factor genes into the patient's body.
Correct Answer is A
Explanation
Choice A rationale:
"Can you describe the triggers for your bleeding episodes?”
This is the correct choice.
Understanding the triggers for bleeding episodes can help determine the type and severity of hemophilia.
For example, frequent spontaneous bleeding without apparent triggers may suggest severe hemophilia, while bleeding triggered by trauma or surgery may indicate a milder form.
Choice B rationale:
"What is the frequency of your joint pain?”
This choice is relevant to assessing the impact of hemophilia on the patient's quality of life but does not directly help determine the type and severity of hemophilia.
Choice C rationale:
"Do you have a family history of hemophilia?”
While family history is important in assessing the risk of hemophilia, it alone does not provide information about the type and severity of the patient's condition.
Choice D rationale:
"Have you been prescribed antifibrinolytic agents?”
This question pertains to treatment rather than the assessment of the type and severity of hemophilia.
It is important to know the treatment history but does not provide direct insight into the condition's severity.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.